Under a tenth of individuals who could benefit from obesity jabs like Wegovy can access them, warns the World Health Organization as it releases its inaugural advice on the medications.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for broader and more equitable availability to these injectable treatments.
Per projections, more than two billion could be living with obesity by 2030 without intervention.
"Our new guidelines acknowledges that obesity is a long-term condition that can be addressed with thorough and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major barriers to widespread availability to the treatments that can aid individuals in losing considerable body mass, explains the organization.
Skinny Jab Supply Crisis
Despite the current best projected outlook, the supply of such drugs could only cover about 100 million people – fewer than 10% of those who need them, per the health organization.
The recommendation calls on countries and companies to widen access, by approaches such as patent sharing.
Exclusive production rights on a key compound – the primary component of Novo Nordisk's Wegovy – is due to expire in multiple countries in 2026.
The Way Obesity Jabs Operate
These medications imitate a biological compound to reduce digestion speed, reduce hunger and boost satiety so individuals eat less.
Individuals usually see weight reduction in the initial weeks of commencing the regular doses.
Evidence suggests users may put most of the weight back on a year later of halting the drug, as their usual food cravings resume.
Being carrying excess weight raises your chance for developing diseases, such as diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity concerns individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.
